Sep 19, 2024 5:30pm EDT

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

Sep 16, 2024 7:30am EDT

Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date

Aug 07, 2024 5:42pm EDT

Medexus Announces Strong Fiscal Q1 2025 Results

Jul 30, 2024 5:30pm EDT

Medexus Schedules First Fiscal Quarter 2025 Conference Call

Jun 25, 2024 5:36pm EDT

Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024

Jun 18, 2024 5:00pm EDT

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call

Jun 06, 2024 10:18am EDT

FDA Accepts for Review Treosulfan NDA Resubmission

May 01, 2024 5:30pm EDT

Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Apr 02, 2024 7:30am EDT

Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Mar 26, 2024 7:53am EDT

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients